Clinical and Experimental Vaccine Research

  • 제11권2호
  • /
  • Pages.173-183
  • /
  • 2022
  • /
  • 2287-3651(pISSN)
  • /
  • 2287-366X(eISSN)
대한백신학회 (The Korean Vaccine Society)
권호 표지
DOI QR코드

DOI QR Code

SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants

  • Rike Syahniar (Department of Microbiology, Faculty of Medicine and Health, Universitas Muhammadiyah Jakarta) ;
  • Dayu Swasti Kharisma (Department of Microbiology, Faculty of Medicine and Health, Universitas Muhammadiyah Jakarta)
  • 투고 : 2021.12.29
  • 심사 : 2022.04.30
  • 발행 : 2022.05.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The coronavirus disease 2019 pandemic has not ended, and several variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus continue to emerge. The emergence of new variants is worrying because higher transmission leads to spikes in infections, vaccine efforts, and other therapeutic developments. Existing literature reports that with new variants affecting vaccine efficacy, hospitalization and risk of a recurrent infection increase. In this review article, we describe the latest variants of SARS-CoV-2, and the impact of each new variant on the efficacy of the developed vaccines reported in the literature and findings. The report concludes that the emergence of a variant that completely evades the immune response and reduces neutralizing antibodies.

키워드

과제정보

We would like to thank the LPPM Universitas Muhammadiyah Jakarta and Faculty of Medicine and Health Universitas Muhammadiyah Jakarta for support of this work.

참고문헌

  1. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021;19:141-54.
  2. Syahniar R, Purba MB, Bekti HS, Mardhia M. Vaccines against coronavirus disease: target proteins, immune responses, and status of ongoing clinical trials. J Pure Appl Microbiol 2020;14:2253-63.
  3. da Rosa Mesquita R, Francelino Silva Junior LC, Santos Santana FM, et al. Clinical manifestations of COVID-19 in the general population: systematic review. Wien Klin Wochenschr 2021;133:377-82.
  4. World Health Organization. World Health Organization Emergencies Programme [Internet]. Geneva: World Health Organization; c2021 [cited 2021 Nov 24]. Available from: https://www.who.int/emergencies/overview.
  5. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19) [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 [cited 2021 Nov 25]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/.
  6. Duan L, Zheng Q, Zhang H, Niu Y, Lou Y, Wang H. The SARS-CoV-2 spike glycoprotein biosynthesis, structure, function, and antigenicity: implications for the design of spike-based vaccine immunogens. Front Immunol 2020;11:576622.
  7. Salvatori G, Luberto L, Maffei M, et al. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines. J Transl Med 2020;18:222.
  8. Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 2020;11:1620.
  9. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARSCoV-2 spike glycoprotein. Cell 2020;181:281-92.
  10. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting December 10, 2020: FDA briefing document. Silver Spring (MD): Food and Drug Administration; 2020.
  11. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403-16.
  12. Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine. N Engl J Med 2021;385:2348-60.
  13. Voysey M, Clemens SA, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99-111.
  14. Centers for Disease Control and Prevention. What you need to know about variants [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2021 [cited 2021 Nov 19]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant.html.
  15. World Health Organization. Tracking SARS-CoV-2 variants [Internet]. Geneva: World Health Organization; 2021 [cited 2021 Nov 21]. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
  16. World Health Organization. The effects of virus variants on COVID-19 vaccines [Internet]. Geneva: World Health Organization; 2021 [cited 2021 Nov 20]. Available from: https://www.who.int/news-room/feature-stories/detail/the-effects-of-virus-variants-on-covid-19-vaccines.
  17. Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARSCoV-2: structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol 2020;10:587269.
  18. Kadam SB, Sukhramani GS, Bishnoi P, Pable AA, Barvkar VT. SARS-CoV-2, the pandemic coronavirus: Molecular and structural insights. J Basic Microbiol 2021;61:180-202.
  19. Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol 2020;41:1100-15.
  20. Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: their roles in pathogenesis. J Microbiol Immunol Infect 2021;54:159-63.
  21. Lauring AS, Hodcroft EB. Genetic variants of SARS-CoV-2: what do they mean? JAMA 2021;325:529-31.
  22. Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 2021;592:616-22.
  23. Galloway SE, Paul P, MacCannell DR, et al. Emergence of SARS-CoV-2 B.1.1.7 Lineage: United States, December 29, 2020-January 12, 2021. MMWR Morb Mortal Wkly Rep 2021;70:95-9.
  24. Slavov SN, Patane JS, Bezerra RD, et al. Genomic monitoring unveil the early detection of the SARS-CoV-2 B.1.351 (beta) variant (20H/501Y.V2) in Brazil. J Med Virol 2021;93:6782-7.
  25. Greaney AJ, Loes AN, Crawford KH, et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 2021;29:463-76.
  26. Tegally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 2021;592:438-43.
  27. de Siqueira IC, Camelier AA, Maciel EA, et al. Early detection of P.1 variant of SARS-CoV-2 in a cluster of cases in Salvador, Brazil. Int J Infect Dis 2021;108:252-5.
  28. Faria NR, Mellan TA, Whittaker C, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science 2021;372:815-21.
  29. Cherian S, Potdar V, Jadhav S, et al. SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. Microorganisms 2021;9:1542.
  30. Mlcochova P, Kemp SA, Dhar MS, et al. SARS-CoV-2 B.1. 617.2 Delta variant replication and immune evasion. Nature 2021;599:114-9.
  31. Uriu K, Kimura I, Shirakawa K, et al. Neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine serum. N Engl J Med 2021;385:2397-9.
  32. Voloch CM, da Silva Francisco R Jr, de Almeida LG, et al. Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. J Virol 2021;95:e00119-21.
  33. World Health Organization. Classification of Omicron (B.1. 1.529): SARS-CoV-2 variant of concern [Internet]. Geneva: World Health Organization; 2021 [cited 2021 Nov 21]. Available from: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variantof-concern.
  34. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med 2021;385:585-94.
  35. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020;383:2603-15.
  36. Lefevre B, Tondeur L, Madec Y, et al. Beta SARS-CoV-2 variant and BNT162b2 vaccine effectiveness in long-term care facilities in France. Lancet Healthy Longev 2021;2:e685-7.
  37. Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med 2021;27:2136-43.
  38. Mahase E. COVID-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ 2021;372:n296.
  39. Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 COVID-19 vaccine. N Engl J Med 2021;385:1172-83.
  40. Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant. N Engl J Med 2021;384:1885-98.
  41. Hitchings MD, Ranzani OT, Dorion M, et al. Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in Sao Paulo. Nat Commun 2021;12:6220.
  42. McMenamin ME, Cowling BJ. CoronaVac efficacy data from Turkey. Lancet 2021;398:1873-4.
  43. Hitchings MD, Ranzani OT, Torres MS, et al. Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: a test-negative case-control study. Lancet Reg Health Am 2021;1:100025.
  44. Ranzani OT, Hitchings MD, Dorion M, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of COVID-19 in Brazil: test negative case-control study. BMJ 2021;374:n2015.
  45. Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med 2021;384:2187-201.
  46. Voko Z, Kiss Z, Surjan G, et al. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study. Clin Microbiol Infect 2022;28:398-404.
  47. Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med 2021;27:1614-21.
  48. Dolzhikova I, Gushchin V, Shcheblyakov D, et al. One-shot immunization with Sputnik Light (the first component of Sputnik V vaccine) is effective against SARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow. medRxiv [Preprint] 2021 Oct 8 [Epub]. https://doi.org/10.1101/2021.10.08.21264715.
  49. Nasreen S, Chung H, He S, et al. Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. Nat Microbiol 2022;7:379-85.
  50. Puranik A, Lenehan PJ, Silvert E, et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv [Preprint] 2021 Aug 21 [Epub]. https://doi.org/10.1101/2021.08.06.21261707.
  51. Abu-Raddad LJ, Chemaitelly H, Butt AA; National Study Group for COVID-19 Vaccination. Effectiveness of the BNT-162b2 COVID-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med 2021;385:187-9.
  52. Charmet T, Schaeffer L, Grant R, et al. Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: results from a nationwide case-control study in France. Lancet Reg Health Eur 2021;8:100171.
  53. Nanduri S, Pilishvili T, Derado G, et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant: National Healthcare Safety Network, March 1-August 1, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1163-6.
  54. Sheikh A, Robertson C, Taylor B. BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the Delta variant. N Engl J Med 2021;385:2195-7.
  55. Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 COVID-19 vaccine against the B.1.351 variant. N Engl J Med 2021;384:1899-909.
  56. Callaway E, Mallapaty S. Novavax offers first evidence that COVID vaccines protect people against variants. Nature 2021;590:17.
  57. Polinski JM, Weckstein AR, Batech M, et al. Effectiveness of the single-dose Ad26.COV2.S COVID vaccine. MedRxiv [Preprint] 2021 Sep 10 [Epub]. https://doi.org/10.1101/2021.09.10.21263385.
  58. Gonzalez S, Olszevicki S, Salazar M, et al. Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina. EClinicalMedicine 2021;40:101126.
  59. Jin P, Li J, Pan H, Wu Y, Zhu F. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need. Signal Transduct Target Ther 2021;6:48.
  60. Ibarrondo FJ, Hofmann C, Ali A, Ayoub P, Kohn DB, Yang OO. Previous infection combined with vaccination produces neutralizing antibodies with potency against SARS-CoV-2 variants. mBio 2021;12:e0265621.
  61. Jongeneelen M, Kaszas K, Veldman D, et al. Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern. bioRxiv [Preprint] 2021 Jul 1 [Epub]. https://doi.org/10.1101/2021.07.01.450707.
  62. Moore PL, Moyo-Gwete T, Hermanus T, et al. Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant. BioRxiv [Preprint] 2021 Jun 9 [Epub]. https://doi.org/10.1101/2021.06.09.447722.
  63. Alter G, Yu J, Liu J, et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature 2021;596:268-72.
  64. Wang P, Nair MS, Liu L, et al. Antibody resistance of SARSCoV-2 variants B.1.351 and B.1.1.7. Nature 2021;593:130-5.
  65. Fernandez J, Bruneau N, Fasce R, et al. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies. J Med Virol 2022;94:399-403.
  66. Chen Y, Shen H, Huang R, Tong X, Wu C. Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac. Lancet Infect Dis 2021;21:1071-2.
  67. Vacharathit V, Aiewsakun P, Manopwisedjaroen S, et al. CoronaVac induces lower neutralising activity against variants of concern than natural infection. Lancet Infect Dis 2021;21:1352-4.
  68. Collier DA, De Marco A, Ferreira IATM, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature 2021;593:136-41.
  69. Supasa P, Zhou D, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell 2021;184:2201-11.
  70. Gushchin VA, Dolzhikova IV, Shchetinin AM, et al. Neutralizing activity of sera from Sputnik V-vaccinated people against variants of concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow endemic SARS-CoV-2 variants. Vaccines (Basel) 2021;9:779.